

## ABSTRACT SUBMISSION GUIDELINES

- + You must be registered for the Symposium to submit an abstract. Please go to <http://auau.auanet.org/node/20818> to register.
- + Please email your name, abstract title and category to [jua-international@urol.or.jp](mailto:jua-international@urol.or.jp) to receive instructions on submitting your abstract via the AUA's online portal.

**ABSTRACT CATEGORIES:** Authors must select a category below

- Bladder Cancer and Upper Tract Urothelial Carcinoma
- BPH & LUTS
- Pediatric Urology
- Prostate Cancer
- Renal Cancer
- Urinary Incontinence, Voiding Dysfunction and Prolapse Management
- Urolithiasis

### PREPARATION OF ABSTRACTS

- 1. Size:** The size of the abstract is limited to 2,280 characters, not including spaces.
- 2. Title:** The title should clearly define the topic and contain no abbreviations. The title should not be in all capital letters. Please ensure this is written how you would like it displayed on the ePoster screens at the meeting.
- 3. Authors:** List the primary author's full name, followed by the other authors' names. Completely spell out the names of all authors using full first name, middle initial and last name. (Please maintain consistency in authors' names on multiple abstracts to avoid duplication in the Author Index.) However the authors' names appear in the system is how they will appear on the ePoster terminals.
- 4. Body of Abstract:** The abstract should be informative and detailed. However your abstract appears online during the submission process is how it will appear in the printer Journal and online.
  - **The body must contain four separate paragraphs:** a) Introduction and Objective, b) Methods, c) Results and d) Conclusions.
  - It is NOT acceptable to state that "The results will be discussed." Inclusion of specific data is helpful to the reviewers.
  - Indicate the major new findings of the study.

- Standard abbreviations may be used as follows: for the first use, spell out the full term and then follow with the abbreviation in parentheses each time thereafter.
- Proprietary names of drugs are not allowed; generic names must be used.

**5. Source of Funding:** Grant support must be indicated on the "Source of Funding" page. If there is no support, "None" must be listed. This is a required field in the submission process. *Abstracts deemed to be purely for marketing purposes will not be accepted.*

**6. Conflict of Interest and Disclosure Statement:** All authors must disclose conflicts of interest. The electronic submission process will not allow abstracts to be submitted without this information being completed for each author listed on the abstract.

## INSTRUCTIONS FOR SUBMISSION

All abstracts must be submitted online via the meeting submission site. To receive this link, please email [jua-international@urol.or.jp](mailto:jua-international@urol.or.jp) with your full name, abstract category and abstract title. You will then receive a link from the AUA with your log in information to the abstract submission site.

Once you receive this email, please log in and begin filling in the title and abstract information and profile information. You may submit multiple abstracts in the same profile. Please do not create multiple accounts. Please ensure that your email and name is correctly spelled, as this is how it will display on the ePoster website.

Upon logging in, you will be directed to the Dashboard. Here, you will be able to edit your information, edit your submission, and complete other necessary action items or tasks. To complete your abstract, click on the title.

Reviewer results will be provided in January. Authors will be notified of their acceptance and sent further guidelines on submitting the PDF of their poster for presentation at the meeting.

**QUESTIONS?** Please contact AUA at [smevorach@auanet.org](mailto:smevorach@auanet.org)